Gastrointestinal stability of therapeutic anti-TNF α IgG1 monoclonal antibodies

被引:39
|
作者
Yadav, Vipul [1 ]
Varum, Felipe [2 ]
Bravo, Roberto [2 ]
Furrer, Esther [2 ]
Basit, Abdul W. [1 ]
机构
[1] UCL, Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England
[2] Tillotts Pharma AG, Baslerstr 15, CH-4310 Rheinfelden, Switzerland
关键词
Infliximab; Adalimumab; Monoclonal antibodies; Oral delivery; Gastrointestinal stability; Tumor necrosis factor alpha (TNF-alpha); COLONIC BACTERIAL METABOLISM; ORAL DELIVERY; PEPTIDE DRUGS; MICROBIOTA; DISEASE; EFFICACY; SAFETY; FLUIDS; ACID;
D O I
10.1016/j.ijpharm.2016.02.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Monoclonal antibodies (mAbs) are highly effective therapeutic agents, administered exclusively by the parenteral route owing to their previously-documented instability in the gastrointestinal (GI) tract when delivered orally. To investigate the extent of the validity of this assumption, the stability of the tumor necrosis factor alpha (TNF-alpha) neutralizing IgG1 mAbs, infliximab and adalimumab, was studied in human GI conditions. In gastric fluid, infliximab and adalimumab degraded rapidly, with complete degradation occurring within 1 min. In small intestinal fluid, the molecules were shown to be more stable, but nonetheless degraded within a short time frame of 30 min. Investigations into the mechanisms responsible for infliximab and adalimumab instability in the small intestine revealed that the proteolytic enzyme elastase, and to a lesser extent the enzymes trypsin and chymotrypsin, was responsible for their degradation. By contrast, in the human colon, 75% and 50% of the dose of infliximab and adalimumab, respectively, were intact after 60 min, with conversion of mAbs into F(ab')2 Fab and Fc fragments detected in colonic conditions. These data indicate that therapeutic IgG1 antibodies are more stable in the colon than in the upper GI tract, therefore highlighting the potential for oral delivery of anti-TNF-alpha mAbs targeted to the colon. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:181 / 187
页数:7
相关论文
共 50 条
  • [31] Possible role of anti-TNF monoclonal antibodies in the treatment of Mycobacterium marinum infection
    Garzoni, Christian
    Adler, Sabine
    Boller, Christoph
    Furrer, HansJakob
    Villiger, Peter M.
    [J]. RHEUMATOLOGY, 2010, 49 (10) : 1991 - 1993
  • [32] Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study
    Ariana Montes
    Eva Perez-Pampin
    Federico Navarro-Sarabia
    Virginia Moreira
    Arturo Rodríguez de la Serna
    Berta Magallares
    Yiannis Vasilopoulos
    Theologia Sarafidou
    Antonio Fernández-Nebro
    María del Carmen Ordóñez
    Javier Narváez
    Juan D Cañete
    Ana Marquez
    Dora Pascual-Salcedo
    Beatriz Joven
    Patricia Carreira
    Manuel J Moreno-Ramos
    Rafael Caliz
    Miguel Angel Ferrer
    Rosa Garcia-Portales
    Francisco J Blanco
    Cesar Magro
    Enrique Raya
    Lara Valor
    Juan J Alegre-Sancho
    Alejandro Balsa
    Javier Martin
    Darren Plant
    John Isaacs
    Ann W Morgan
    Anne Barton
    Anthony G Wilson
    Juan J Gómez-Reino
    Antonio Gonzalez
    [J]. Arthritis Research & Therapy, 17
  • [33] GENERATION OF MONOCLONAL MURINE ANTI-DNP-IGE, IGM AND IGG1 ANTIBODIES - BIOCHEMICAL AND BIOLOGICAL CHARACTERIZATION
    BOHN, A
    KONIG, W
    [J]. IMMUNOLOGY, 1982, 47 (02) : 297 - 311
  • [34] Anti-TNF antibodies and the ischemic heart
    Frolkis, Inna
    Gurevitch, Jacob
    Yuhas, Yael
    Matsa, Menachem
    Paz, Yosef
    Yakirevich, Vladimir
    [J]. Israel Journal of Medical Sciences, 1996, 32 (Suppl):
  • [35] Mucosal Healing with Anti-TNF Antibodies
    Chevaux, Jean-Baptiste
    Vavricka, Stephan R.
    Rogler, Gerhard
    Lakatos, Peter L.
    Schoepfer, Alain
    Peyrin-Biroulet, Laurent
    [J]. DIGESTION, 2012, 86 : 16 - 22
  • [36] FcR-Mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of IBD
    Levin, Alon D.
    Wildenberg, Manon E.
    D'Haens, Geert R.
    van den Brink, Gijs R.
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S637 - S638
  • [37] FcR-mediated effector function contributes to the therapeutic response of anti-TNF monoclonal antibodies in a mouse model of IBD
    Levin, A.
    Wildenberg, M.
    D'Haens, G.
    van den Brink, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S16 - S16
  • [38] MONOCLONAL GAMMOPATHY (IGG1) IN PSORIASIS
    SANMIGUEL, J
    CORRALES, A
    LOPEZBORRASCA, A
    [J]. DERMATOLOGICA, 1982, 164 (04): : 289 - 289
  • [39] ANTI-DRUG-ANTIBODIES BUT NOT IGG-4 ANTIBODIES AGAINST TNF BLOCKERS INFLUENCE THE ACTIVITY OF ANTI-TNF DRUGS IN RHEUMATOID ARTHRITIS
    Benucci, M.
    Infantino, M.
    Manfredi, M.
    Olivito, B.
    Sarzi-Puttini, P.
    Atzeni, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 431 - 431
  • [40] Effect of digestion on stability of palivizumab IgG1 in the infant gastrointestinal tract
    Lueangsakulthai, Jiraporn
    Kim, Bum Jin
    Demers-Mathieu, Veronique
    Sah, Baidya Nath P.
    Woo, Yeonhee
    Olyaei, Amy
    Aloia, Molly
    O'Connor, Ann
    Scottoline, Brian P.
    Dallas, David C.
    [J]. PEDIATRIC RESEARCH, 2021, 90 (02) : 335 - 340